Faron Pharmaceuticals Oy · LSE:FARN
Faron Pharmaceuticals Oy — Investor Presentation (September 2026)
33 slides from Faron Pharmaceuticals Oy's investor presentation, September 2026
Slide 1: Faron Pharmaceuticals Ltd Non-confidential corporate deck
2026 Faron Pharmaceuticals Ltd Non-confidential corporate deck 1 FARON PHARMACEUTICALS LTD | 2026 NON-CONFIDENTIAL CORPORATE DECK
Slide 2: Corporate Disclaimer
Corporate Disclaimer THIS DOCUMENT, ITS CONTENTS AND ANY INFORMATION PROVIDED AT THIS PRESENTATION ARE STRICTLY CONFIDENTIAL AND ARE FOR DISCUSSION PURPOSES ONLY AND MUST NOT BE RELIED UPON FOR ANY PURPOSE. THIS DOCUMENT IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY
Slide 3: Introduction to Faron and HR MDS
Introduction to Faron and HR MDS Faron is a clinical stage immunotherapy company with proven efficacy in Phase 2 that it can 1 overcome treatment resistance in difficult to treat cancers. Lead focus is high-risk myelodysplastic syndrome (HR MDS). HR MDS is a lethal form of blood 2 cancer causing sev
Slide 4: Bexmarilimab Pipeline
Bexmarilimab Pipeline Bexmarilimab development is most advanced in HR-MDS while also showing significant potential in multiple other indications and settings Phase of development Treatment Indication(s) Anticipate key milestones Preclinical Phase I Phase II Phase III Bexmarilimab + Azacitidine First
Slide 5: CLEVER-1 is an immunosuppressive receptor highly expressed in MDS and other hematological malignancies
CLEVER-1 is an immunosuppressive receptor highly expressed in MDS and other hematological malignancies CLEVER-1 expression in Finnish biobank samples CLEVER-1 from patients with HaemOnc malignancies ▪ A scavenger receptor expressed by leukemic myeloid B-ALL BCL/TCL cells and immunosuppressive macrop
Slide 6: Faron's CLEVER-1 solution
Faron’s CLEVER-1 solution Bexmarilimab (anti-Clever-1 mAb). One of the first drugs to tackle the core biology of HR MDS by activating the immune system and improving cancer cell killing Bexmarilimab inhibits 1 2 Bexmarilimab deactivates CLEVER-1 to cause immune the energy production of cell reprogra
Slide 7: BEXMAB Phase 1/2 data
BEXMAB Phase 1/2 data FARON PHARMACEUTICALS LTD | 2026 NON-CONFIDENTIAL CORPORATE DECK
Slide 8: BEXMAB Phase 1/2 Study: very high-risk and difficult to treat population
BEXMAB Phase 1/2 Study: very high-risk and difficult to treat population Treatment-naïve HR- MDS (n=21) r/r HR-MDS (n=34) ECOG PS, n (%) Study population: 0 4 (19.0) 9 (25.6) 1 15 (71.4) 21 (61.8) ▪ MDS: treatment naive intermediate, high/very high –risk 2 2 (9.5) 4 (11.8) ▪ MDS: failure to HMA (r/r
Slide 9: Frontline HR-MDS patients had strong responses to bexmarilimab even in this very high-risk population
Frontline HR-MDS patients had strong responses to bexmarilimab even in this very high-risk population The majority of patients fully clear bone marrow blasts including mTP53 patients – 85% ORR 45% Overall CR rate using 2006 IWG mTP53 wt TP53 0 16 Duration of CR in months Best % change in BM -30 blas
Slide 10: Strong results seen also in last line population
Strong results seen also in last line population r/r MDS Total n=33a IWG2006b CR 2 (6) mCR 14 (42) PR 2 (6) HI 3 (9) SD 8 (24) NR/PD 4 (12) ORR 21/33 (64%) Best percent change in bone marrow blast percentage during BEX+AZA treatment in rr HR MDS patients. Best decrease within aspirate or biopsy repo
Slide 11: Bexmarilimab demonstrates strong outcomes in HR MDS versus currently available options
Bexmarilimab demonstrates strong outcomes in HR MDS versus currently available options As a first-line combination therapy for Frontline HR MDS Complete Remission rates treatment-naive HR MDS patients, Complete Remission (CR) is expected Bexmarilimab + 45% to double compared to azacitidine Azacitidi
Slide 12: Bex increases the production of healthy blood cells and appears to improve the safety of single agent Aza
Bex increases the production of healthy blood cells and appears to improve the safety of single agent Aza BEXMAB study – key clinically meaningful safety endpoints compared with historical azacitidine data 66% Neutropenia 40% 70% Thrombocytopenia 35% 51% Anaemia 38% Aza alone 1 11% TEAEs leading to
Slide 13: Induction of hematopoiesis in the bone marrow of deeply cytopenic HR-MDS patients after Bex & Aza
Induction of hematopoiesis in the bone marrow of deeply cytopenic HR-MDS patients after Bex & Aza Bone marrow biopsy Bone marrow biopsy after when entering the trial 3 cycles of Bex+Aza Eo-Baso-Mast Precursor CXCL8hi Erythroid Precursor TGFB1hi MPP-MkEry/MEP PPARG+ LGALS2+ S100A12hi Increase in prog
Slide 14: Development Plan for Frontline Approval per FDA Guidance
Development Plan for Frontline Approval per FDA Guidance 2026 2027 2028 2029 2030 2031 H1 H2 H1 H2 H1 H2 H1 H2 H1 H2 H1 H2 Ph2 N ~ 350 total (Ph2 + Ph 3) ~256 patients needed for the Phase 3 if CR N ~90 (30 per arm) alone is the endpoint – with confirmatory OS follow-up Bexmarilimab 3mg/kg + Follow-
Slide 15: Between 2026 and 2028, multiple value inflection points anticipated for Bexmarilimab
Between 2026 and 2028, multiple value inflection points anticipated for Bexmarilimab Haem Solid Lead Program Phase IIb BEXMAB-2 trial FPI Phase IIb BEXMAB-2 trial readout Phase III BEXMAB-3 trial FPI 2026 2027 2028 Contracted IITs BLAZE Bex + PD-1 combo FPI BLAZE first data readout BLAZE second data
Slide 16: Strong fundamentals of the core business
Strong fundamentals of the core business Large, underserved market Best-in-class efficacy Differentiated safety profile, in high-risk MDS (HR MDS) in completed Phase I/II rare for an HR MDS candidate ~40,000 new patients annually across 45% CR rate with 16 month duration 57% transfusion independence
Slide 17: HR MDS Market Landscape
HR MDS Market Landscape FARON PHARMACEUTICALS LTD | 2026 NON-CONFIDENTIAL CORPORATE DECK
Slide 18: Apart from hypomethelating agents or stem cell transplant, there are no treatments for HR-MDS
Apart from hypomethelating agents or stem cell transplant, there are no treatments for HR-MDS* HR-MDS patient journey1 270 k MDS Patients in the US & EU3 50% 50% Low-risk MDS High-risk MDS 85% 15% 30-40% progress to Not eligible for Eligible for intensive High-risk MDS4 intensive therapy therapy No
Slide 19: Faron is leading the era of disease modifying agents
Faron is leading the era of disease modifying agents Recent developments in the field puts Faron in a leading position for HR MDS ▪ Faron has emerged as the leading candidate in HR MDS with differentiated novel biology and an adaptive development plan taking into account past failures. ▪ Other conte
Slide 20: Faron is forecasting significant sales in HR MDS alone
Faron is forecasting significant sales in HR MDS alone Faron is forecasting approximately just under $2 Bn in sales Bexmarilimab Revenue by Region from HR-MDS alone at peak in 2042. $2 000 Millions The lack of competition, high unmet need and orphan drug $1 800 designation all make for a commercial
Slide 21: Bexmarilimab in Solid Tumors
Bexmarilimab in Solid Tumors FARON PHARMACEUTICALS LTD | 2026 NON-CONFIDENTIAL CORPORATE DECK
Slide 22: Proof of principle of modulating the tumor microenvironment (TME) in solid tumors
Proof of principle of modulating the tumor microenvironment (TME) in solid tumors Phase 1/2 First-in-Human MATINS Trial Highlights • 216 patients treated across 10 different cancer types • Targeting Clever-1 with bexmarilimab is well tolerated, RP2D 1mg/kg Q3W supported by the FDA • Bex converts int
Slide 23: Bex – a drug for IFNg low “cold” (Clever-1 high) tumors
Bex – a drug for IFNg low “cold” (Clever-1 high) tumors Single agent Bex treated melanoma Anti-PD1 treated melanoma patients according to patients according to IFN gamma status3 IFN gamma status1,2 Pts achieving disease control Pts not achieving disease control Faron’s bexmarilimab aims to tackle th
Slide 24: Management Team
Management Team Dr. Juho Jalkanen, CEO Jurriaan Dekkers, CFO Dr. Maija Hollmén, CSO Dr. Petri Bono, CMO Ralph Hughes, CBO Heikki Jouttijärvi, CTO 24 FA FRAO RNO NP HPAHRAMRAMCAEC U ET U I CTAI L CSA LL S T DL T I D H A| L2F0- Y 2 E6 AN R ORNE-PCOORNTF, IJDAENNUTAIRAYL- JCUONREP 2O0R2A6T E D E C K
Slide 25: Scientific Advisory Board
Scientific Advisory Board Our Scientific Advisory Board is comprised of world leading immunologists and oncologists as well as industry professionals that have led significant R&D programs to successful commercialization of products. Toni Choueiri, MD, FASCO Naval G. Daver, MD Professor Professor Ha
Slide 26: Thank You
Thank You FARON PHARMACEUTICALS LTD | 2026 NON-CONFIDENTIAL CORPORATE DECK
Slide 27: APPENDIX
APPENDIX FARON PHARMACEUTICALS LTD | 2026 NON-CONFIDENTIAL CORPORATE DECK
Slide 28: The more CLEVER-1 is inhibited, the deeper the clinical response in combination with Aza
The more CLEVER-1 is inhibited, the deeper the clinical response in combination with Aza in HR MDS patients Target engagement data with bexmarilimab and sClever-1 data shows a clear and statistically significant relationship between target engagement with bexmarilimab and response – the more target
Slide 29: Frontline HR MDS Efficacy by Dose
Frontline HR MDS Efficacy by Dose • Majority (7/12; 58%) of the patients with full clearence of BM blasts are form the 3mg/kg BEX dose group • 3mg/kg group was NOT enriched in low blast count patients but rather majority had >10% BM blasts at Screening Best percent change in bone marrow blast percen
Slide 30: Increased toxicity seen with 6 mg/kg
Increased toxicity seen with 6 mg/kg Total 1mg/kg Doublet 3mg/kg Doublet 6mg/kg Doublet Adverse Events (N=55), n (%) (N=4), n (%) (N=25), n (%) (N=26), n (%) Total AEs 55 (100) 4 (100) 25 (100) 26 (100) TEAEs 55 (100) 4 (100) 25 (100) 26 (100) ≥ Grade 3 TEAEs 48 (87) 3 (75) 21 (84) 24 (92) Serious T
Slide 31: Longest survival seen with Bex 3mg/kg
Longest survival seen with Bex 3mg/kg r/r MDS OS data: 1. The overall mOS in this population was 14.5 months: 1. 3mg/kg: 440 days – 14.7 months 2. 6mg/kg: 282 days – 9.4 months 3. Expected survival is 4-6 months in this population The data in mOS in r/r makes two points clear: 1. 3mg/kg BEX confers
Slide 32: Bexmarilimab – MoA in more detail
Bexmarilimab – MoA in more detail The first drug to tackle the core biology of HR MDS 1 Bexmarilimab deactivates the energy production of CLEVER-1 is an immunosuppressive receptor on macrophages immune cells, responsible for 3 the cancer cells, enabling existing therapies. (ie. AZA), eliminating inf
Slide 33: Bexmarilimab - Mechanism of Action
Bexmarilimab - Mechanism of Action Bexmarilimab plays a key role in normalizing the bone marrow microenvironment Sensitizing leukemic stem cells and juvenile blasts to HMAs in the bone marrow niche by interfering with Mitochondrial respiration Increasing antigen presentation of monocytes and cancer
Faron Pharmaceuticals — Investor Presentation (September 2026) on 6ix